- Mundipharma announces vision to focus on technology and providing game-changing healthcare solutions
- New vision exemplified by digital Asthma app that incorporates wide range of smart phone capabilities to address historically poor inhaler technique
Singapore, 21 April 2017: Mundipharma has announced it is taking a new approach to healthcare, underpinned by a vision to harness technology in order to provide game-changing healthcare solutions and deliver superior patient outcomes. In the first example of this announced publicly, Mundipharma has launched breatheriteTM, an innovative mobile app that employs augmented reality technology to address errors in inhaler use among Asthma sufferers.
This is the latest in a series of digital initiatives developed by Mundipharma out of its Regional Head Office in Singapore.
The Head Office also acts as an innovation hub where digital ideation and content creation takes place. In the last two years, mobile apps and digital initiatives have been developed for all its therapy areas – analgesia, oncology, oncology supportive care, ophthalmology, respiratory and consumer healthcare. Mundipharma have been early adopters of innovative technology including, virtual reality, augmented reality and gamification.
These initiatives have been primarily focused on medical education for both doctors and patients and have been developed in response to ongoing unmet needs.
To create an environment in which these ground-breaking initiatives can be rapidly developed, and deployed for doctors and patients in the emerging markets where Mundipharma operates, the organisation is transforming its whole business – from R&D to Supply Chain – to become a digital healthcare company.
Mundipharma believes this digitisation approach will also create other benefits and efficiencies that together will give it a unique point of difference in the industry, increase access to important medicines and enable a more patient centric approach.
Mundipharma CEO, Raman Singh, said “Mundipharma has embarked on an exciting and unique journey to become a digital healthcare company and own this space. We are investing in new technology, and we’re prepared to undergo a bold transformation.”
The evidence of this is apparent in the digital healthcare initiatives Mundipharma has already rolled out, including the revolutionary breatheriteTM app.
This is the digital first initiative Mundipharma announced publically because it is available to all patients, and in the lead up to World Asthma Day, Mundipharma wants as many Asthma sufferers as possible to start benefiting from this revolutionary solution to a 40-year old problem.
breatheriteTM is the first digital health platform to utilise augmented reality together with a range of smartphone sensors, delivering a personal asthma management solution with a focus on correcting errors in inhaler technique. The app engages the front-facing camera for facial mapping, the accelerometer and gyrometer to track inhaler preparation, the microphone to analyse inhalation and exhalation, along with augmented reality to visualise correct inhaler orientation and head alignment. It also enables patients to set medication reminders, receive lifestyle tips, real-time weather and air quality information.
“The high rates of smartphone penetration across emerging markets and the processing power of today’s mobile devices together with the increasing maturity of augmented reality technology have combined to create a real opportunity to tackle this decades old problem,” said Mundipharma CEO Raman Singh. “With World Asthma Day approaching, we are proud to launch this unparalleled new solution, which gives people with Asthma an opportunity to take greater control of their condition, and exemplifies the new direction of Mundipharma.”
Mundipharma’s independent associated companies are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
For more information please visit: www.mundipharma.com.sg
For further information please contact:
Head of Communications & Digital Strategy –
Asia Pacific, Middle East, Africa & Latin America
+65-6303-9732 | email@example.com
In 2016, a large independent study, “The Systematic Review of Errors Inhaler Technique” 144 articles reporting on a total number of 54,354 subjects with inhaler error were summarised. The study concluded that “Incorrect inhaler technique is unacceptably frequent and has not improved over the past 40 years, pointing to an urgent need for new approaches to education and drug delivery.” 1
1Joaquin Sanchis, Ignasi Gich, and Soren Pedersen, Aerosol Drug Management Improvement Team (ADMIT), CHEST 2016; 150(2): 394
™ : breatherite is a trademark of Mundipharma